{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:16:15Z","timestamp":1776374175860,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12913-016-1902-8","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T13:10:55Z","timestamp":1479129055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases"],"prefix":"10.1186","volume":"16","author":[{"given":"Thomas","family":"Staab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Isbary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker E.","family":"Amelung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Ruof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"key":"1902_CR1","unstructured":"Bundesiministerium f\u00fcr Gesundheit. [Gesetz zur Neuordnung des Arzneimittelmarktes - AMNOG]. 2011. http:\/\/www.bundesgesundheitsministerium.de\/service\/begriffe-von-a-z\/a\/arzneimittelmarktneuordnungsgesetz-amnog.html . Accessed 15 Sep 2016."},{"key":"1902_CR2","unstructured":"G-BA. [Verfahrensordnung des Gemeinsamen Bundesausschusses]. 2016. https:\/\/www.g-ba.de\/downloads\/62-492-1243\/VerfO_2016-03-17_iK-2016-08-23.pdf . Accessed 15 Sep 2016."},{"key":"1902_CR3","unstructured":"Deutscher Bundestag. [Sozialgesetzbuch (SGB) F\u00fcnftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477, letzte \u00c4nderung durch Artikel 3 des Gesetzes vom 20. Dezember 2012 (BGBI. I S. 2781))]. 1988. http:\/\/www.gesetze-im-internet.de\/bundesrecht\/sgb_5\/gesamt.pdf . Accessed 15 Sep 2016."},{"issue":"2","key":"1902_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.healthpol.2014.08.004","volume":"118","author":"J Ruof","year":"2014","unstructured":"Ruof J, Knoerzer D, Duenne AA, Dintsios CM, Staab T, Schwartz FW. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany. Health Policy. 2014;118(2):242\u201354.","journal-title":"Health Policy"},{"issue":"3","key":"1902_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40268-015-0100-1","volume":"15","author":"J Ruof","year":"2015","unstructured":"Ruof J, Fluckiger O, Andre N. Early benefit assessments in oncology in Germany: how can a clinically relevant endpoint not be relevant to patients? Drugs R D. 2015;15(3):221\u20136.","journal-title":"Drugs R D"},{"issue":"1","key":"1902_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2191-1991-4-2","volume":"4","author":"I Dabisch","year":"2014","unstructured":"Dabisch I, Dethling J, Dintsios CM, Drechsler M, Kalanovic D, Kaskel P, et al. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Econ Rev. 2014;4(1):2\u20139.","journal-title":"Health Econ Rev"},{"key":"1902_CR7","doi-asserted-by":"crossref","unstructured":"Kvitkina T, ten Haaf A, Reken S, McGauran N, Wieseler B. Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences [Patientenrelevante Endpunkte und Surrogate in der fr\u00fchen Nutzenbewertung von Arzneimitteln: erste Erfahrungen]. Z Evid Fortbild Qual Gesundhwesen. 2014;108(8-9):528\u201338.","DOI":"10.1016\/j.zefq.2014.06.015"},{"issue":"2-3","key":"1902_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.healthpol.2013.12.008","volume":"116","author":"H H\u00f6rn","year":"2014","unstructured":"H\u00f6rn H, Nink K, McGauran N, Wieseler B. Early benefit assessment of new drugs in Germany - results from 2011 to 2012. Health Policy. 2014;116(2-3):147\u201353.","journal-title":"Health Policy"},{"key":"1902_CR9","unstructured":"G-BA. Overview of products [\u00dcbersicht der Wirkstoffe]. 2016. http:\/\/www.g-ba.de\/informationen\/nutzenbewertung\/ . Accessed 15 Sep 2016."},{"issue":"4","key":"1902_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/bcp.13023","volume":"82","author":"G Tafuri","year":"2016","unstructured":"Tafuri G, Pagnini M, Moseley J, Massari M, Petavy F, Behring A, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82(4):965\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1902_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0b013e3181b9c5ec","volume":"15","author":"D Lebwohl","year":"2009","unstructured":"Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386\u201394.","journal-title":"Cancer J"},{"issue":"12","key":"1902_CR12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2007.14.8064","volume":"26","author":"DJ Sargent","year":"2008","unstructured":"Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008;26(12):1922\u20133.","journal-title":"J Clin Oncol"},{"key":"1902_CR13","first-page":"39","volume":"22","author":"C Axelrod","year":"2010","unstructured":"Axelrod C. The significance of progression-free survival as a clinical end point in oncology. Drug Benefit Trends. 2010;22:39\u201345.","journal-title":"Drug Benefit Trends"},{"key":"1902_CR14","unstructured":"European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus (CPMP\/EWP\/1080\/00 Rev. 1). 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129256.pdf . Accessed 15 Sep 2016."},{"key":"1902_CR15","unstructured":"Committee for proprietary medicinal products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus (Report No.: CPMP\/EWP\/1080\/00). 2002. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003262.pdf . Accessed 15 Sep 2016."},{"key":"1902_CR16","unstructured":"Ble\u00df H-H, de Millas C, Kern B, Seidlitz C, Talaschus A. Auswirkungen von Stellungnahmen der Wissenschaft in der Nutzenbewertung von Arzneimitteln. 2016. https:\/\/www.mynewsdesk.com\/material\/document\/55081\/download . Accessed 15 Sep 2016."},{"key":"1902_CR17","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie (DGHO). Nutzenbewertung von Arzneimitteln der Onkologie und H\u00e4matologie - eine Standortbestimmung. 2013. http:\/\/www.dgho.de\/informationen\/gesundheitspolitische-schriftenreihe\/dgho_gpsr_arzneimittelnutzenbewertung.pdf . Accessed 15 Sep 2016."},{"key":"1902_CR18","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie (DGHO). DGHO erweitert Informationsplattform Onkopedia um den Bereich Arzneimittel Bewertung. 2016. https:\/\/www.dgho.de\/informationen\/presse\/pressemitteilungen\/dgho-erweitert-informationsplattform-onkopedia-um-den-bereich-arzneimittel-bewertung . Accessed 15 Sep 2016."},{"issue":"1","key":"1902_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13561-014-0012-8","volume":"4","author":"V Ivandic","year":"2014","unstructured":"Ivandic V. Requirements for benefit assessment in Germany and England - overview and comparison. Health Econ Rev. 2014;4(1):12.","journal-title":"Health Econ Rev"},{"key":"1902_CR20","unstructured":"Novartis. Zometa Summary of Product Characteristics. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000336\/WC500051730.pdf . Accessed 15 Sep 2016."},{"key":"1902_CR21","unstructured":"ICH Expert Working Group. ICH Harmonised tripartite guideline - Statistical principles for clinical trials - E9. 1998. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E9\/Step4\/E9_Guideline.pdf . Accessed 15 Sep 2016."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-016-1902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-016-1902-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-016-1902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:31:41Z","timestamp":1498361501000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-016-1902-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1186\/s12913-016-1902-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]},"article-number":"651"}}